NMN has become a global anti-ageing sensation, attracting growing interest across search engines and social media. The rapid rise has put the supplement at the centre of longevity discussions.

NMN is marketed as a way to restore NAD+, a molecule involved in energy production and cellular repair. But the human research is delivering a more cautious verdict.

More than a dozen human trials have tested NMN since 2020, but the clearest result is that it raises blood NAD+ levels. That does not prove it slows ageing or helps people live longer.

No human trial has shown that NMN extends lifespan. No trial has yet measured cognition as a primary outcome, and there is no human evidence that NMN causes weight loss.

Animal studies have linked NMN with improved insulin action and slower cognitive decline in mouse models of Alzheimer's disease. Those findings fuel interest, but remain unconfirmed in humans.

NMN forms in the body from vitamin B3 via an enzyme called NAMPT. Once absorbed by cells, it can be converted into NAD+, which is why researchers have focused on NMN as an oral precursor.

What Clinical Trials Show

The most consistent human finding is an increase in blood NAD+. A 2022 trial found a 38 per cent rise in the NAD+/NADH ratio after 60 days at 300 milligrams daily.

A Japanese trial also reported higher NAD+ levels after 12 weeks at 250 milligrams daily. Together, the studies support the biological effect driving interest in NMN.

A six-week trial involving 48 amateur runners tested 300, 600 and 1,200 milligrams daily. The 600- and 1,200-milligram groups improved on several measures of aerobic capacity.

Not every measure of aerobic performance changed. The finding is encouraging, but does not establish NMN as a general fitness enhancer.

A 2021 Washington University School of Medicine trial found improved muscle insulin sensitivity and signalling in postmenopausal women with prediabetes. Fasting glucose did not significantly change.

Other trials have reported better sleep quality and improved skin elasticity. These findings come from small studies and need replication before they can be considered reliable.

The longevity question remains unanswered. Despite the supplement's anti-ageing appeal, no human study has demonstrated that NMN can extend lifespan or slow the ageing process itself.

NMN's closest rival, nicotinamide riboside, also raises NAD+ and has been tested in more published human trials overall. A short 2026 trial compared the two and found that both raised circulating NAD+.

That means claims that NMN is superior remain unproven. The same caution applies to claims of a longevity advantage.

Safety and Product Quality

Short-term safety results are reassuring. A 2026 systematic review found no clear increase in adverse events or liver abnormalities, but the evidence remains limited.

The review covered doses from 250 to 2,000 milligrams daily and studies lasting two to 24 weeks. It also noted that rare, delayed and long-term risks cannot yet be excluded.

Product quality presents another concern for consumers. A 2024 analysis of 18 NMN supplements found measured amounts ranging from 100 per cent below label claims to 11.2 per cent above them.

Three of the 18 products contained no detectable NMN. That finding highlights the importance of third-party purity testing.

There is no established dose for extending human lifespan. Trial doses vary, while evidence that more NMN delivers greater benefits remains limited.

For now, the science supports a narrower conclusion than the anti-ageing hype suggests. NMN can raise NAD+ levels and may affect some health measures, but it has not been shown to help humans live longer.

Read more